{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:00:24Z","timestamp":1762430424460,"version":"3.37.3"},"reference-count":81,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.2515\/therapie\/2009063","type":"journal-article","created":{"date-parts":[[2010,3,8]],"date-time":"2010-03-08T10:25:04Z","timestamp":1268043904000},"page":"39-46","source":"Crossref","is-referenced-by-count":5,"title":["Suivi th\u00e9rapeutique pharmacologique de la lamotrigine"],"prefix":"10.1016","volume":"65","author":[{"given":"Dani\u00e8le","family":"Bentu\u00e9-Ferrer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Tribut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Cl\u00e9mence","family":"Verdier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2008","article-title":"R\u00e9sum\u00e9 des Caract\u00e9ristiques du Produit de la lamotrigine","series-title":"\u00c9ditions du Vidal","key":"10.2515\/therapie\/2009063_bb0010"},{"key":"10.2515\/therapie\/2009063_bb0015","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1586\/14737175.9.2.167","article-title":"Once-daily lamotrigine extended release for epilepsy management","volume":"9","author":"Rheims","year":"2009","journal-title":"Expert Rev Neurother"},{"key":"10.2515\/therapie\/2009063_bb0020","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.2165\/00003495-200363190-00009","article-title":"Lamotrigine: a review of its use in bipolar disorder","volume":"63","author":"Goldsmith","year":"2003","journal-title":"Drugs"},{"key":"10.2515\/therapie\/2009063_bb0025","first-page":"421","article-title":"Lamotrigine in the treatment of pain syndromes and neuropathic pain","volume":"109","author":"Titlic","year":"2008","journal-title":"Bratisl LekListy"},{"key":"10.2515\/therapie\/2009063_bb0030","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1517\/17425255.2.6.1009","article-title":"Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy","volume":"2","author":"Biton","year":"2006","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.2515\/therapie\/2009063_bb0035","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2165\/00003495-199550040-00008","article-title":"An update of its pharmacology and therapeutic use in epilepsy","volume":"50","author":"Fitton","year":"1995","journal-title":"Drugs"},{"key":"10.2515\/therapie\/2009063_bb0040","doi-asserted-by":"crossref","first-page":"152","DOI":"10.2165\/00003495-199346010-00009","article-title":"Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy","volume":"46","author":"Goa","year":"1993","journal-title":"Drugs"},{"issue":"Suppl 5","key":"10.2515\/therapie\/2009063_bb0045","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1111\/j.1528-1157.1999.tb00917.x","article-title":"Lamotrigine","volume":"40","author":"Matsuo","year":"1999","journal-title":"Epilepsia"},{"key":"10.2515\/therapie\/2009063_bb0050","first-page":"351","article-title":"Lamotrigine","volume":"138","author":"Walker","year":"1999","journal-title":"Antiepileptic drugs"},{"key":"10.2515\/therapie\/2009063_bb0055","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/clpt.1987.193","article-title":"Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans","volume":"42","author":"Cohen","year":"1987","journal-title":"Clin Pharmacol Ther"},{"key":"10.2515\/therapie\/2009063_bb0060","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1046\/j.1528-1157.2003.46902.x","article-title":"Tolerability and pharmacokinetics of oral loading with lamotrigine in epilepsy monitoring units","volume":"44","author":"Lardizabal","year":"2003","journal-title":"Epilepsia"},{"key":"10.2515\/therapie\/2009063_bb0065","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1592\/phco.19.6.437.31052","article-title":"Pharmacokinetics of lamotrigine in children in the absence of other antiepileptic drugs","volume":"19","author":"Chen","year":"1999","journal-title":"Pharmacotherapy"},{"issue":"Suppl 1","key":"10.2515\/therapie\/2009063_bb0070","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1177\/0883073897012001041","article-title":"Lamotrigine: pharmacokinetics","volume":"12","author":"Garnett","year":"1997","journal-title":"J Child Neurol"},{"key":"10.2515\/therapie\/2009063_bb0075","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2165\/00003088-199325060-00003","article-title":"Lamotrigine clinical pharmacokinetics","volume":"25","author":"Rambeck","year":"1993","journal-title":"Clin Pharmacokinet"},{"key":"10.2515\/therapie\/2009063_bb0080","first-page":"659","article-title":"Food reduces the bioavailability of lamotrigine","volume":"121","author":"Sharma","year":"2005","journal-title":"Indian J Med Res"},{"issue":"Suppl 2","key":"10.2515\/therapie\/2009063_bb0085","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1111\/j.1528-1157.1991.tb05883.x","article-title":"Clinical pharmacology of lamotrigine","volume":"32","author":"Peck","year":"1991","journal-title":"Epilepsia"},{"key":"10.2515\/therapie\/2009063_bb0090","first-page":"517","article-title":"Comparison of plasma and saliva concentrations of lamotrigine in healthy volunteers","volume":"57","author":"Incecayir","year":"2007","journal-title":"Arzneimittelforschung"},{"key":"10.2515\/therapie\/2009063_bb0095","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.jocn.2005.12.037","article-title":"Monitoring salivary lamotrigine concentrations","volume":"13","author":"Malone","year":"2006","journal-title":"J Clin Neurosci"},{"key":"10.2515\/therapie\/2009063_bb0100","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/00007691-200010000-00003","article-title":"and serum concentration of lamotrigine in patients with epilepsy","volume":"22","author":"Tsiropoulos","year":"2000","journal-title":"Ther Drug Monit"},{"key":"10.2515\/therapie\/2009063_bb0105","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1046\/j.1365-2125.1997.00594.x","article-title":"Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data","volume":"43","author":"Hussein","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"10.2515\/therapie\/2009063_bb0110","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0920-1211(91)90012-5","article-title":"Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy","volume":"10","author":"Ramsay","year":"1991","journal-title":"Epilepsy Res"},{"key":"10.2515\/therapie\/2009063_bb0115","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.seizure.2008.05.009","article-title":"Smoking reduces serum levels of lamotrigine","volume":"17","author":"Reinsberger","year":"2008","journal-title":"Seizure"},{"key":"10.2515\/therapie\/2009063_bb0120","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.yebeh.2003.11.018","article-title":"Concerns regarding lamotrigine and breast feeding","volume":"5","author":"Liporace","year":"2004","journal-title":"Epilepsy Behav"},{"key":"10.2515\/therapie\/2009063_bb0125","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1528-1157.2000.tb00232.x","article-title":"Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation","volume":"41","author":"Ohman","year":"2000","journal-title":"Epilepsia"},{"key":"10.2515\/therapie\/2009063_bb0130","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1528-1157.1996.tb00605.x","article-title":"Concentration-effect and concentration-toxicity relations with lamotrigine: a prospective study","volume":"37","author":"Kilpatrick","year":"1996","journal-title":"Epilepsia"},{"key":"10.2515\/therapie\/2009063_bb0135","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1528-1157.1997.tb01111.x","article-title":"The concentration-effect relationship with lamotrigine (LTG)","volume":"38","author":"Gidal","year":"1997","journal-title":"Epilepsia"},{"key":"10.2515\/therapie\/2009063_bb0140","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1059-1311(96)80063-X","article-title":"Combination vigabatrin and lamotrigine therapy for intractable epilepsy","volume":"5","author":"Schapel","year":"1996","journal-title":"Seizure"},{"key":"10.2515\/therapie\/2009063_bb0145","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00007691-199706000-00002","article-title":"The influence of dosage, age, and comedication on steady state plasma lamotrigine concentrations in epileptic children: a prospective study with preliminary assessment of correlations with clinical response","volume":"19","author":"Bartoli","year":"1997","journal-title":"Ther Drug Monit"},{"key":"10.2515\/therapie\/2009063_bb0150","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000066165","article-title":"Therapeutic drug monitoring of lamotrigine in patients suffering from resistant partial seizures","volume":"48","author":"Benetello","year":"2002","journal-title":"Eur Neurol"},{"key":"10.2515\/therapie\/2009063_bb0155","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.seizure.2007.11.023","article-title":"Lamotrigine therapeutic thresholds","volume":"17","author":"Sondergaard Khinchi","year":"2008","journal-title":"Seizure"},{"issue":"Suppl.6","key":"10.2515\/therapie\/2009063_bb0160","first-page":"72","article-title":"Is there a relationship between the occurence of adverse events from lamotrigine and its serum concentrations","volume":"39","author":"Kanner","year":"1998","journal-title":"Epilepsia"},{"key":"10.2515\/therapie\/2009063_bb0165","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1684\/j.1950-6945.2002.tb00436.x","article-title":"Prospective study on concentration-efficacy and concentration-toxicity: correlations with lamotrigine serum levels","volume":"4","author":"Fr\u00f6scher","year":"2002","journal-title":"Epileptic Disord"},{"key":"10.2515\/therapie\/2009063_bb0170","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1212\/01.WNL.0000138424.33979.0C","article-title":"Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy","volume":"63","author":"Hirsch","year":"2004","journal-title":"Neurology"},{"key":"10.2515\/therapie\/2009063_bb0175","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.chiabu.2006.04.009","article-title":"Lamotrigine poisoning presenting as seizures: a case of deliberate poisoning","volume":"31","author":"Willis","year":"2007","journal-title":"Child Abuse Negl"},{"key":"10.2515\/therapie\/2009063_bb0180","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1067\/mpd.2002.125256","article-title":"Efficacy, tolerability, and kinetics of lamotrigine in infants","volume":"141","author":"Mikati","year":"2002","journal-title":"J Pediatr"},{"key":"10.2515\/therapie\/2009063_bb0185","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00228-007-0308-2","article-title":"Lamotrigine in children and adoles cents: the impact of age on its serum concentrations and on the extent of drug interactions","volume":"63","author":"Reimers","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"10.2515\/therapie\/2009063_bb0190","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1177\/0091270007313391","article-title":"Population pharmacokinetics of lamotrigine in elderly patients","volume":"48","author":"Punyawudho","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.2515\/therapie\/2009063_bb0195","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2125.1997.tb00028.x","article-title":"Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers","volume":"43","author":"Wootton","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"10.2515\/therapie\/2009063_bb0200","first-page":"25","article-title":"Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis","volume":"19","author":"Fillastre","year":"1993","journal-title":"Drugs Exp Clin Res"},{"key":"10.2515\/therapie\/2009063_bb0205","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1046\/j.1365-2125.2001.01389.x","article-title":"Influence of cirrhosis on lamotrigine pharmacokinetics","volume":"51","author":"Marcellin","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.2515\/therapie\/2009063_bb0210","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1212\/WNL.59.2.251","article-title":"Lamotrigine clearance during pregnancy","volume":"59","author":"Tran","year":"2002","journal-title":"Neurology"},{"key":"10.2515\/therapie\/2009063_bb0215","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1212\/01.WNL.0000133213.10244.FD","article-title":"Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study","volume":"63","author":"de Haan","year":"2004","journal-title":"Neurology"},{"key":"10.2515\/therapie\/2009063_bb0220","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.eplepsyres.2005.06.004","article-title":"Individual changes in lamotrigine plasma concentrations during pregnancy","volume":"65","author":"Petrenaite","year":"2005","journal-title":"Epilepsy Res"},{"key":"10.2515\/therapie\/2009063_bb0225","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/FTD.0b013e318178e2a9","article-title":"Changes in lamotrigine pharmacokinetics during pregnancy and the puerperium","volume":"30","author":"Franco","year":"2008","journal-title":"Ther Drug Monit"},{"key":"10.2515\/therapie\/2009063_bb0230","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1212\/01.wnl.0000289511.20864.2a","article-title":"Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency","volume":"70","author":"Pennell","year":"2008","journal-title":"Neurology"},{"key":"10.2515\/therapie\/2009063_bb0235","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eplepsyres.2009.02.011","article-title":"Prospectively assessed changes in lamotrigine-concentration in women with epilepsy during pregnancy, lactation and the neonatal period","volume":"85","author":"Fotopoulou","year":"2009","journal-title":"Epilepsy Res"},{"key":"10.2515\/therapie\/2009063_bb0240","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/j.1528-1167.2007.01471.x","article-title":"Plasma concentrations of lamotrigine and its 2-N-glucuronide metabolite during pregnancy in women with epilepsy","volume":"49","author":"Ohman","year":"2008","journal-title":"Epilepsia"},{"key":"10.2515\/therapie\/2009063_bb0245","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1124\/dmd.109.026609","article-title":"Up-regulation of UDP-glucuronosyltransferase(UGT) 1A4 by 17beta-estradiol: a potential mechanism of increased lamotrigine elimination in pregnancy","volume":"37","author":"Chen","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.2515\/therapie\/2009063_bb0250","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2125.1989.tb03514.x","article-title":"The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinemia (Gilbert\u2019s syndrome)","volume":"28","author":"Posner","year":"1989","journal-title":"Br J Clin Pharmacol"},{"key":"10.2515\/therapie\/2009063_bb0255","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.seizure.2007.03.006","article-title":"Perioperative fluctuations of lamotrigine serum levels in patients undergoing epilepsy surgery","volume":"16","author":"Paul","year":"2007","journal-title":"Seizure"},{"key":"10.2515\/therapie\/2009063_bb0260","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/hup.999","article-title":"A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder","volume":"24","author":"Schieber","year":"2009","journal-title":"Hum Psychopharmacol"},{"key":"10.2515\/therapie\/2009063_bb0265","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0924-9338(02)00002-0","article-title":"Clinically relevant reduction of lamotrigine concentrations by carbamazepine","volume":"18","author":"Koch","year":"2003","journal-title":"Eur Psychiatry"},{"key":"10.2515\/therapie\/2009063_bb0270","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1212\/01.WNL.0000076485.09353.7A","article-title":"Oral contraceptives reduce lamotrigine plasma levels","volume":"61","author":"Sabers","year":"2003","journal-title":"Neurology"},{"key":"10.2515\/therapie\/2009063_bb0275","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0920-1211(01)00305-9","article-title":"Lamotrigine plasma levels reduced by oral contraceptives","volume":"47","author":"Sabers","year":"2001","journal-title":"Epilepsy Res"},{"key":"10.2515\/therapie\/2009063_bb0280","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1212\/01.wnl.0000344167.78102.f0","article-title":"Valproate and lamotrigine level variation with menstrual cycle phase and oral contraceptive use","volume":"72","author":"Herzog","year":"2009","journal-title":"Neurology"},{"key":"10.2515\/therapie\/2009063_bb0285","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s002280000146","article-title":"Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects","volume":"56","author":"Ebert","year":"2000","journal-title":"Eur J Clin Pharmacol"},{"key":"10.2515\/therapie\/2009063_bb0290","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1111\/j.1528-1167.2005.10105.x","article-title":"Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations","volume":"46","author":"Reimers","year":"2005","journal-title":"Epilepsia"},{"key":"10.2515\/therapie\/2009063_bb0295","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/j.1552-4604.1996.tb04228.x","article-title":"Effect of felbamate on the pharmacokinetics of lamotrigine","volume":"36","author":"Colucci","year":"1996","journal-title":"J Clin Pharmacol"},{"key":"10.2515\/therapie\/2009063_bb0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0920-1211(96)01018-2","article-title":"Lamotrigine pharmacokinetics in patients receiving felbamate","volume":"27","author":"Gidal","year":"1997","journal-title":"Epilepsy Res"},{"key":"10.2515\/therapie\/2009063_bb0305","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.clpt.2006.04.014","article-title":"Lopinavir\/ritonavir reduces lamotrigine plasma concentrations in healthy subjects","volume":"80","author":"van der Lee","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.2515\/therapie\/2009063_bb0310","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1592\/phco.26.5.627","article-title":"Lack of pharmacokinetic interaction between lamotrigine and olanzapine in healthy volunteers","volume":"26","author":"Jann","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.2515\/therapie\/2009063_bb0315","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1365-2125.2006.02598.x","article-title":"Pharmacokinetics and tolerability of lamotrigine and olanzapine coadministered to healthy subjects","volume":"61","author":"Sidhu","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.2515\/therapie\/2009063_bb0320","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1038\/sj.npp.1300831","article-title":"Lack of pharmacokinetic interaction between oxcarbazepine and lamotrigine","volume":"30","author":"Theis","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.2515\/therapie\/2009063_bb0325","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1059-1311(98)80074-5","article-title":"Lamotrigine toxicity secondary to sertraline","volume":"7","author":"Kaufman","year":"1998","journal-title":"Seizure"},{"key":"10.2515\/therapie\/2009063_bb0330","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1046\/j.1528-1157.2002.37701.x","article-title":"Lack of an effect of topiramate on lamotrigine serum concentrations","volume":"43","author":"Berry","year":"2002","journal-title":"Epilepsia"},{"key":"10.2515\/therapie\/2009063_bb0335","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1046\/j.1528-1157.2003.64402.x","article-title":"Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients","volume":"44","author":"Doose","year":"2003","journal-title":"Epilepsia"},{"key":"10.2515\/therapie\/2009063_bb0340","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2125.1992.tb04079.x","article-title":"Sodium valproate acutely inhibits lamotrigine metabolism","volume":"33","author":"Yuen","year":"1992","journal-title":"Br J Clin Pharmacol"},{"key":"10.2515\/therapie\/2009063_bb0345","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1212\/WNL.55.4.588","article-title":"Adding valproate to lamotrigine: a study of their pharmacokinetic interaction","volume":"55","author":"Kanner","year":"2000","journal-title":"Neurology"},{"key":"10.2515\/therapie\/2009063_bb0350","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/01.ftd.0000153403.99478.1f","article-title":"Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy","volume":"27","author":"Levy","year":"2005","journal-title":"Ther Drug Monit"},{"key":"10.2515\/therapie\/2009063_bb0355","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jchromb.2004.12.004","article-title":"Determination of lamotrigine in small volumes of plasma by high-performance liquid chromatography","volume":"817","author":"Cheng","year":"2005","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.2515\/therapie\/2009063_bb0360","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/chromsci\/47.6.478","article-title":"Development and validation of a rapid column-switching high-performance liquid chromatographic method for the determination of lamotrigine in human serum","volume":"47","author":"Brunetto Mdel","year":"2009","journal-title":"J Chromatogr Sci"},{"key":"10.2515\/therapie\/2009063_bb0365","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jchromb.2007.12.020","article-title":"Determination of lamotrigine in whole blood with on line solid phase extraction","volume":"863","author":"Bompadre","year":"2008","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.2515\/therapie\/2009063_bb0370","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1002\/jssc.200700110","article-title":"Rapid HPLC analysis of the antiepileptic lamotrigine and its metabolites in human plasma","volume":"30","author":"Saracino","year":"2007","journal-title":"J Sep Sci"},{"key":"10.2515\/therapie\/2009063_bb0375","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jpba.2008.11.030","article-title":"LC method for the therapeutic drug monitoring of lamotrigine: evaluation of the assay performance and validation of its application in the routine area","volume":"49","author":"Zufia","year":"2009","journal-title":"J Pharm Biomed Anal"},{"key":"10.2515\/therapie\/2009063_bb0380","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jchromb.2007.06.023","article-title":"Robust isocratic high performance liquid chromatographic method for simultaneous determination of seven antiepileptic drugs including lamotrigine, oxcarbazepine and zonisamide in serum after solid-phase extraction","volume":"857","author":"Vermeij","year":"2007","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.2515\/therapie\/2009063_bb0385","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/chromsci\/45.9.616","article-title":"Drug monitoring: simultaneous analysis of lamotrigine, oxcarbazepine, 10-hydroxycarbazepine, and zonisamide by HPLC-UV and a rapid GC method using a nitrogenphosphorus detector for levetiracetam","volume":"45","author":"Greiner-Sosanko","year":"2007","journal-title":"J Chromatogr Sci"},{"key":"10.2515\/therapie\/2009063_bb0390","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jchromb.2007.04.006","article-title":"Development of a simple column-switching high performance liquid chromatography (HPLC) method for rapid and simultaneous routine serum monitoring of lamotrigine, oxcarbazepine and 10-monohydroxycarbazepine (MHD)","volume":"854","author":"Greiner","year":"2007","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.2515\/therapie\/2009063_bb0395","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/01.ftd.0000245779.64080.30","article-title":"Determination of lamotrigine and its metabolites in human plasma by liquid chromatography-mass spectrometry","volume":"28","author":"Beck","year":"2006","journal-title":"Ther Drug Monit"},{"key":"10.2515\/therapie\/2009063_bb0400","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/FTD.0b013e31818580b3","article-title":"Seradyn quantitative microsphere system lamotrigine immunoassay on a Hitachi 911 analyzer compared with HPLC-UV","volume":"30","author":"Westley","year":"2008","journal-title":"Ther Drug Monit"},{"key":"10.2515\/therapie\/2009063_bb0405","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/00007691-200412000-00007","article-title":"Long-term follow-up using a higher target range for lamotrigine monitoring","volume":"26","author":"Morris","year":"2004","journal-title":"Ther Drug Monit"},{"key":"10.2515\/therapie\/2009063_bb0410","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716306461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716306461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T01:49:54Z","timestamp":1739929794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716306461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S0040595716306461"],"URL":"https:\/\/doi.org\/10.2515\/therapie\/2009063","relation":{},"ISSN":["0040-5957"],"issn-type":[{"type":"print","value":"0040-5957"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}